Report On Experiences with Excipient Audits
The industry initiative EXCiPACT was launched a year ago to improve monitoring of pharmaceutical excipients. At the CPHI China in Shanghai and the ExcipientFest Europe in Amsterdam, the auditors of blue inspection body have now drawn an initial conclusion: “Overall, the level of awareness for good manufacturing and good distribution practices at excipient manufacturers has increased significantly in the past 12 months,” declared lead auditor Dr Norbert Waldöfner in a presentation at the IPEC China Excipient Regulatory and Quality Control Seminar during the CPHI in Shanghai. “This is certainly partly due to the fact that the regulatory authorities have placed a stronger focus on the topic.” Shortly before, one of blue’s shareholders, Dr Stefan Kettelhoit had already informed the participants at the ExcipientFest congress Europe in Amsterdam about the experiences with the first EXCiPACT audits.
One difficulty with audits of excipients such as lactose, cellulose or glycerol is that GMP and GDP standards do not apply to all parts of the company being audited, explained Dr Norbert Waldöfner: “In many cases, only a small part of production is destined for the pharmaceutical industry.” In such cases, documentation of the respective batches is particularly important.
EXCiPACT initiative aims for certified monitoring of excipients
The EXCiPACT initiative was established by industrial associations of excipient suppliers and the pharmaceuticals industry. The aim is to merge and standardise surveillance audits of Good Manufacturing and Good Distribution Practice of pharmaceutical excipients. “The slogan is ‘Less but more professional audits’, meaning that EXCiPACT has defined particularly high standards for every single audit”, explained Dr Stefan Kettelhoit from blue inspection body GmbH: “This ensures that third-party audits of excipient manufacturers are also internationally recognised by regulatory bodies.” In the past, pharmaceutical companies conducted their own audits, which meant that excipient manufacturers were sometimes confronted with over 100 audit requests from different customers.
CPHI China and ExcipientFest Europe
CPHI China is part of CPHI Worldwide. With around 30,000 visitors from 102 countries, the trade fair in Shanghai is one of the largest events for contract manufacturers and exporters of pharmaceutical products worldwide. The ExcipientFest congress is specifically aimed at producers and users of excipients for the production of medicinal products. It is staged alternately at venues in the United States, Europe and Asia.
The blue inspection body GmbH examines the Good Manufacturing Practices (GMP) of pharmaceutical companies around the globe. Third-party audits by blue efficiently relieve manufacturing authorisation holders, API suppliers and API manufacturers. Blue inspection body GmbH is the first independent and accredited service provider for GMP audits in the European Union.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance